Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00001100 · ClinicalTrials.gov registry record · Phase 3
A Phase III Study to Evaluate the Safety and Efficacy of Ganciclovir (Dihydroxypropoxymethyl Guanine [DHPG]) Treatment of Symptomatic Central Nervous System (CNS) Congenital Cytomegalovirus (CMV) Infections.
A Phase 3 study of Cytomegalovirus Infections, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 3
- Development phase
- 130
- Enrollment target
- 1
- Study location
NCT00001100 is a Phase 3 study of Cytomegalovirus Infections that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 130 participants, below the 197-participant average among 24 other Cytomegalovirus Infections trials with a reported enrollment target (34% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00001100, a Phase 3 study of Cytomegalovirus Infections, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 130 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate the benefits and safety of the antiviral drug ganciclovir (DHPG) given intravenously to treat newborn infants who are born infected with cytomegalovirus (CMV). CMV is a herpes virus that can infect most organs of the body, resulting in death in 10-30% of babies with symptoms of CMV. It can cause severe brain damage in a large percentage of surviving babies. Children in this study have a CMV infection of the central nervous system (CNS).
Conditions Studied
Interventions
- DRUG ganciclovir
Study Locations (1)
Alabama
- NIAID/DMID/CASG Central Unit - Birmingham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 130 participants |
| Est. Completion | 2005-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00001100
The ClinicalTrials.gov registry entry for NCT00001100 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 130 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 197-participant average among 24 other Cytomegalovirus Infections trials with a reported enrollment target (34% lower). The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cytomegalovirus Infections appearing as the primary indexed condition, and to 1 intervention - of which ganciclovir is the first listed.
NCT00001100 reports 1 study location spanning 1 distinct geographic area - top geographies include Alabama.
Frequently Asked Questions
What is clinical trial NCT00001100 about?
NCT00001100 is a clinical study titled "A Phase III Study to Evaluate the Safety and Efficacy of Ganciclovir (Dihydroxypropoxymethyl Guanine [DHPG]) Treatment of Symptomatic Central Nervous System (CNS) Congenital Cytomegalovirus (CMV) Infections.". The purpose of this study is to evaluate the benefits and safety of the antiviral drug ganciclovir (DHPG) given intravenously to treat newborn infants who are born infected with cytomegalovirus (CMV). CMV is a herpes virus that can infect most organs of the body, resulting in death in 10-30% of babi...
What is the current status of trial NCT00001100?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 130 participants. Estimated completion is 2005-11.
What conditions does trial NCT00001100 study?
This clinical trial studies the following conditions: Cytomegalovirus Infections.
What interventions are being tested in trial NCT00001100?
The interventions under investigation include: ganciclovir (DRUG).
Who is sponsoring clinical trial NCT00001100?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00001100 being conducted?
This trial has 1 study location across Alabama. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cytomegalovirus Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Letermovir (Prevymis) for CMV in Kidney and Pancreas Transplant Recipients
RECRUITING · Phase 3
-
A Study of Valacyclovir Hydrochloride in the Prevention of Life-Threatening Cytomegalovirus Disease in HIV-Infected Patients
COMPLETED · Phase 3
-
Prophylactic Use of Maribavir for the Prevention of Cytomegalovirus (CMV) Disease in Stem Cell Transplant Recipients
COMPLETED · Phase 3
-
The Safety and Effectiveness of Adefovir Dipivoxil in the Treatment of HIV-Infected Patients
COMPLETED · Phase 3
-
Letermovir for Secondary Prophylaxis in Solid Organ Transplant Recipients
RECRUITING · Phase 4
-
Open Label Trial of Oral Letermovir for CMV Prophylaxis in Thoracic Transplant Recipients
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.